The oval/football-shaped blue pill debossed with “Y” on one side and “2 0” (or “20”) on the reverse is Alprazolam 1 mg, manufactured by Aurobindo Pharma USA. It is a generic formulation of Xanax and belongs to the benzodiazepine drug class. In the United States, it is classified as a Schedule IV (C-IV) controlled substance due to its potential for misuse, dependence, and addiction.
Pill Identification
Attribute – Specification
- Imprint – Y on one side / 2 0 (or 20) on the other side
- Active Ingredient – Alprazolam (1 mg)
- Color – Light blue to blue
- Shape – Oval / Elliptical (often referred to as a “blue football”)
- Manufacturer – Aurobindo Pharma Limited / Aurobindo Pharma USA
- Drug Class – Benzodiazepine / Anxiolytic
- DEA Schedule – Schedule IV (C-IV) |
Mechanism of Action
Alprazolam is a fast-acting triazolo-benzodiazepine that works as a positive allosteric modulator at the gamma-aminobutyric acid type A receptor complex in the central nervous system (CNS):
- Enhancing GABA Activity: Alprazolam binds to a distinct regulatory site on the receptor, enhancing the binding affinity of GABA (the primary inhibitory neurotransmitter in the brain).
- Chloride Influx: This binding increases the frequency of chloride channel openings, allowing chloride ions to enter the postsynaptic neuron. The hyperpolarized cell membrane suppresses neuronal firing and reduces CNS hyperexcitability.
- Pharmacokinetics: Alprazolam is absorbed rapidly after oral administration, reaching peak blood plasma concentrations within 1 to 2 hours. It has a mean elimination half-life of approximately 11 hours (ranging from 6 to 27 hours in healthy adults).
Indications and Dosage
Alprazolam is indicated for the acute management of Generalized Anxiety Disorder (GAD) and Panic Disorder (with or without agoraphobia).
- Generalized Anxiety Disorder (Adults):
- Initial Dose: 0.25 mg to 0.5 mg administered 3 times daily.
- Titration: Doses may be adjusted at intervals of 3 to 4 days up to a maximum daily dose of 4 mg/day in divided doses.
- Panic Disorder (Adults):
- Initial Dose: 0.5 mg administered 3 times daily.
- Titration: May be increased by no more than 1 mg/day every 3 to 4 days. Therapeutic maintenance doses often range between 3 to 6 mg/day, with some patients requiring up to 10 mg/day under close supervision.
- Administration & Duration:
- Take orally with or without food.
- Intended for short-term use (typically 2 to 4 weeks) due to the rapid development of tolerance and physical dependence.
Side Effects
Common Side Effects
- Drowsiness, sedation, and lethargy
- Impaired coordination, ataxia, and dizziness
- Memory impairment and concentration difficulties
- Dry mouth, constipation, and changes in appetite/weight
- Slurred speech and blurred vision
Serious Adverse Reactions
- Severe Respiratory Depression: Dangerously shallow or stopped breathing, especially when combined with other central nervous system depressants.
- Paradoxical Reactions: Acute agitation, rage, irritability, hallucinations, or behavioral disinhibition.
- Depression & Suicidal Ideation: Emergence or worsening of clinical depression and suicidal thoughts.
- Severe Physical Dependence & Withdrawal: Rapid onset of rebound panic attacks, tremors, delirium, or seizures if discontinued abruptly.
Precautions and Drug Interactions
- Opioids and CNS Depressants: Concurrent use with opioids, alcohol, sedatives, or hypnotics leads to additive CNS depression and markedly increases the risk of fatal overdose.
- CYP3A4 Inhibitors & Inducers: Alprazolam is heavily cleared by hepatic CYP3A enzymes. Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) drastically increase alprazolam blood concentrations and toxicity risk. Strong inducers (e.g., carbamazepine, St. John’s wort) decrease efficacy.
- Contraindications: Severe respiratory depression, sleep apnea, myasthenia gravis, severe hepatic insufficiency, and acute narrow-angle glaucoma.
- Pregnancy & Breastfeeding: Crosses the placenta and enters breast milk. Exposure during late pregnancy can cause neonatal flaccidity (“floppy infant syndrome”), respiratory difficulties, and neonatal withdrawal syndrome.
Critical Warnings (FDA Boxed Warnings)
- Risks from Concomitant Use with Opioids: Combining benzodiazepines and opioids may cause profound sedation, respiratory depression, coma, and death.
- Abuse, Misuse, and Addiction: Use of alprazolam exposes patients to risks of abuse and addiction, which can lead to overdose or death.
- Dependence and Withdrawal Reactions: Physical dependence can develop rapidly, even with regular short-term use.
- Do Not Discontinue Abruptly: Sudden cessation or rapid dose reduction can trigger life-threatening withdrawal symptoms, including status epilepticus (continuous seizures), psychosis, hallucinations, and intense rebound anxiety. Discontinuation requires a gradual, medically supervised tapering schedule.